Fused tricyclic compounds as adenosine receptor antagonist

Abstract

The present disclosure relates to fused tricyclic compounds of formula (I) or its tautomers, polymorphs, stereoisomers, prodrugs, solvate or a pharmaceutically acceptable salts, or pharmaceutical compositions containing them and methods of treating conditions and diseases that are mediated by thereof as A2A adenosine receptor antagonists. [Formula should be inserted here] The compounds of the present disclosure are useful in the treatment, prevention or suppression of diseases and disorders that may be susceptible to improvement by the mediation of adenosine A2A receptor.; Such conditions include, but are not limited to, Parkinsons disease, restless leg syndrome, Alzheimers disease, neurodegenerative disorder, inflammation, wound healing, dermal fibrosis, nocturnal myoclonus, cerebral ischaemia, myocardial ischemia, Huntington's disease, multiple system atrophy, corticobasal degeneration, Wilson's disease or other disorders of basal ganglia which results in dyskinesias, post traumatic stress disorder, hepatic cirrhosis, sepsis, spinal cord injury, retinopathy, hypertension, social memory impairment, depression, neuroprotection, narcolepsy or other sleep related disorders, attention deficit hyperactivity disorder, drug addiction, post traumatic stress disorder and vascular injury and the like. The present disclosure also relates to methods for the preparation of such compounds, and to pharmaceutical compositions containing them.

Description

technical field

[0001] The present invention relates to a series of substituted fused tricyclic compounds, their tautomers, polymorphs, stereoisomers, prodrugs, solvates, pharmaceutically acceptable salts, pharmaceutical compositions containing them and Methods of treatment of conditions and diseases mediated by adenosine receptor (AR) activity. These compounds are useful in the treatment, prevention or inhibition of diseases and disorders which are readily ameliorated by antagonism of adenosine receptors. The invention also relates to processes for the preparation of such compounds and pharmaceutical compositions containing them. Background technique

[0002] The actions of adenosine are mediated through at least four specific cell membrane receptors that are currently identified and classified as belonging to the G protein-coupled receptor family A 1 、A 2A 、A 2B and A 3 . A 1 and A 3 The receptor downregulates cellular cAMP levels by coupling to G proteins that inh...

Images